THE Australian Therapeutic
Goods Administration-approved
Novartis’ Ultibro Breezhaler 110/50
(indacaterol/glycopyrronium) in
March this year for maintenance
treatment of chronic obstructive
pulmonary disease (COPD) and
the dual bronchodilator is now
available on a private prescription.The above article was sent to subscribers in Pharmacy Daily's issue from 06 Aug 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Aug 14
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.